Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

1. Saura, C.
2. Hlauschek, D.
3. Oliveira, M.
4. Zardavas, D.
5. Jallitsch-Halper, A.
6. de la Peña, L.
7. Nuciforo, P.
8. Ballestrero, A.
9. Dubsky, P.
10. Lombard, J.M.
11. Vuylsteke, P.
12. Castaneda, C.A.
13. Colleoni, M.
14. Santos Borges, G.
15. Ciruelos, E.
16. Fornier, M.
17. Boer, K.
18. Bardia, A.
19. Wilson, T.R.
20. Stout, T.J.
21. Hsu, J.Y.
22. Shi, Y.
23. Piccart, M.
24. Gnant, M.
25. Baselga, J.
26. de Azambuja, E.
27. Erakutsi egile guztiak +